fixed dose combination [Bioanalytics]

posted by avinash – India, 2015-03-06 12:18 (3733 d 08:45 ago) – Posting: # 14551
Views: 6,756

Dear Members,

Please let me know, If a fixed dose combination is administered during clinical phase of BA/BE study, where in, different methods are used for analysis; is it sufficient to check the specificity of the analyte in presence of other drug administered along with long term stability, or should a complete method validation is required with the analyte of interest in presence of other FDC drug in QC samples.

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
29 visitors (0 registered, 29 guests [including 9 identified bots]).
Forum time: 22:04 CEST (Europe/Vienna)

An expert is someone who knows some of the worst mistakes
that can be made in his subject,
and how to avoid them.    Werner Heisenberg

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5